摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-3-(3-Fluoro-4-methyl-phenyl)-5-hydroxymethyl-oxazolidin-2-one | 1072827-28-1

中文名称
——
中文别名
——
英文名称
(S)-3-(3-Fluoro-4-methyl-phenyl)-5-hydroxymethyl-oxazolidin-2-one
英文别名
(5S)-3-(3-fluoro-4-methylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one
(S)-3-(3-Fluoro-4-methyl-phenyl)-5-hydroxymethyl-oxazolidin-2-one化学式
CAS
1072827-28-1
化学式
C11H12FNO3
mdl
——
分子量
225.22
InChiKey
POPOLGDPJCYSJL-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    49.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (S)-3-(3-Fluoro-4-methyl-phenyl)-5-hydroxymethyl-oxazolidin-2-one甲基磺酰氯N,N-二异丙基乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 1.0h, 以100%的产率得到Methanesulfonic acid (S)-3-(3-fluoro-4-methyl-phenyl)-2-oxo-oxazolidin-5-ylmethyl ester
    参考文献:
    名称:
    [EN] OXAZOLIDINYL ANTIBIOTICS
    [FR] ANTIBIOTIQUES OXAZOLIDINYLE
    摘要:
    公开号:
    WO2010041218A3
  • 作为产物:
    参考文献:
    名称:
    [EN] TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS
    [FR] COMPOSÉS ANTIBIOTIQUES OXAZOLIDINONE TRICYCLIQUE
    摘要:
    该发明涉及式(I)的抗菌化合物,其中“-----”是键或不存在,V是CH,CR 6或N; R 0是H或如果“-----”是键,则也可以是烷氧基; R 1主要是H或卤素; 当“-----”是键时,U是CH或N,或者如果“-----”不存在,则U是CH 2,NH或NR 9; R 2是H,烷基羰基或-CH 2 -R 3; R 3是H,烷基或羟基烷基; R 4是H或如果n不为0且R 5为H,则也可以是OH; R 5是H,烷基,羟基烷基,氨基烷基,烷氧基烷基,羧基或烷氧羰基; R 6是羟基烷基,羧基,烷氧羰基或-(CH 2 ) q -NR 7 R 8,其中q为1、2或3,且R 7和R 8中的每一个独立地是H或烷基,或R 7和R 8与携带它们的N原子形成一个环; R 9是烷基或羟基烷基; A是-(CH 2 ) p-,-CH 2 CH 2 CH(OH)-或-COCH 2 CH(OH)-; G是取代苯基或G 1或G 2,其中Q是O或S,X是CH或N; Y 1、Y 2和Y 3每个可以是CH或N; 当A为-CH 2 CH 2 CH(OH)-或-COCH 2 CH(OH)-时,n为0,当A为-(CH 2 ) p-,p为1、2、3或4时,n为0、1或2,但n和p的总和为2、3或4; 以及这些化合物的盐。
    公开号:
    WO2010041194A1
点击查看最新优质反应信息

文献信息

  • OXAZOLIDINONE ANTIBIOTICS
    申请人:Bur Daniel
    公开号:US20110039823A1
    公开(公告)日:2011-02-17
    The invention relates to compounds of formula (I) wherein U, V, W, X, R1, R2, R3, R4, R5, R6, A, B, D, E, G, m, and n are as defined in the description, to pharmaceutically acceptable salts of such compounds for use in the manufacture of a medicament for the prevention or treatment of a bacterial infection. Certain compounds of formula (I) are new and are also part of this invention.
    本发明涉及式(I)的化合物,其中U、V、W、X、R1、R2、R3、R4、R5、R6、A、B、D、E、G、m和n的定义如说明书中所述,还涉及用于制造预防或治疗细菌感染的药物的上述化合物的药用可接受盐。式(I)中的某些化合物是新颖的,也是本发明的一部分。
  • TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS
    申请人:Hubschwerlen Christian
    公开号:US20110195961A1
    公开(公告)日:2011-08-11
    The invention relates to antibacterial compounds of formula I wherein is a bond or is absent, V is CH, CR 6 or N; R 0 is H or, if is a bond, may also be alkoxy; R 1 is notably H or halogen; U is CH or N when is a bond, or, if is absent, U is CH 2 , NH or NR 9 ; R 2 is H, alkylcarbonyl or —CH 2 —R 3 ; R 3 is H, alkyl or hydroxyalkyl; R 4 is H or, if n is not 0 and R 5 is H, may also be OH; R 5 is H, alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, carboxy or alkoxycarbonyl; R 6 is hydroxyalkyl, carboxy, alkoxycarbonyl or —(CH 2 ) q —NR 7 R 8 , q being 1, 2 or 3 and each of R 7 and R 8 independently being H or alkyl or R 7 and R 8 forming with the N atom bearing them a ring; R 9 is alkyl or hydroxyalkyl; A is —(CH 2 ) p —, —CH 2 CH 2 CH(OH)— or —COCH 2 CH(OH)—; G is substituted phenyl or G 1 or G 2 wherein Q is O or S and X is CH or N; and Y 1 , Y 2 and Y 3 may each be CH or N; and n is 0 when A is —CH 2 CH 2 CH(OH)— or —COCH 2 CH(OH)—, and n is 0, 1 or 2 when A is —(CH 2 ) p —, p being 1, 2, 3 or 4, with the proviso that the sum of n and p is then 2, 3 or 4; and to salts of such compounds.
    该发明涉及式I的抗菌化合物,其中: - 当V为CH或N时,U为CH或N,R1为H或卤素,R2为H、烷基羰基或—CH2—R3,R3为H或烷基羟基,R4为H或OH(当n不为0且R5为H时),R5为H、烷基、羟基烷基、基烷基、烷基烷基、羧基或烷羰基,R6为羟基烷基、羧基、烷羰基或—( )q—NR7R8,其中q为1、2或3,且R7和R8各自独立地为H或烷基,或者R7和R8与它们所带的N原子形成一个环; - 当V为CR6时,U为 、NH或NR9,R0为H或烷基,R1为H或卤素,R2为H、烷基羰基或— —R3,R3为H或烷基羟基,R4为H或OH(当n不为0且R5为H时),R5为H、烷基、羟基烷基、基烷基、烷基烷基、羧基或烷羰基,R6为羟基烷基、羧基、烷羰基或—( )q—NR7R8,其中q为1、2或3,且R7和R8各自独立地为H或烷基,或者R7和R8与它们所带的N原子形成一个环; - 当V为一条键时,U为CH或N,R0为H或烷基,R1为H或卤素,R2为H、烷基羰基或— —R3,R3为H或烷基羟基,R4为H或OH(当n不为0且R5为H时),R5为H、烷基、羟基烷基、基烷基、烷基烷基、羧基或烷羰基,R6为羟基烷基、羧基、烷羰基或—( )q—NR7R8,其中q为1、2或3,且R7和R8各自独立地为H或烷基,或者R7和R8与它们所带的N原子形成一个环;A为—( )p—、— CH(OH)—或—CO CH(OH)—,G为取代基或G1或G2,其中Q为O或S,X为CH或N,Y1、Y2和Y3各自可以为CH或N;n当A为— CH(OH)—或—CO CH(OH)—时为0,当A为—( )p—时,n为0、1或2,p为1、2、3或4,但n和p的和必须为2、3或4;以及这些化合物的盐。
  • Oxazolidinone antibiotics
    申请人:Actelion Pharmaceuticals Ltd
    公开号:US08217029B2
    公开(公告)日:2012-07-10
    The invention relates to compounds of formula (I) wherein U, V, W, X, R1, R2, R3, R4, R5, R6, A, B, D, E, G, m, and n are as defined in the description, to pharmaceutically acceptable salts of such compounds for use in the manufacture of a medicament for the prevention or treatment of a bacterial infection. Certain compounds of formula (I) are new and are also part of this invention.
    本发明涉及式(I)的化合物,其中U、V、W、X、R1、R2、R3、R4、R5、R6、A、B、D、E、G、m和n在说明书中定义,以及这些化合物的药学上可接受的盐,用于制造用于预防或治疗细菌感染的药物。式(I)的某些化合物是新的,也是本发明的一部分。
  • Oxazolidinyl antibiotics
    申请人:Hubschwerlen Christian
    公开号:US08507478B2
    公开(公告)日:2013-08-13
    The invention relates to antibacterial compounds of formula I wherein R1 is alkoxy or halogen; U and V each independently are CH or N; is a bond or is absent; W is CH or N or, when is absent, W is CH2 or NH, with the proviso that U, V and W are not all N; A is a bond or CH2; R2 is H or, provided A is CH2, may also be OH; m and n each independently are 0 or 1; D is CH2 or a bond; G represents a phenyl group substituted once or twice in the meta and/or para position(s) by substituents selected from alkyl, (C1-C3)alkoxy and halogen, or G is a group G1 or G2 wherein Z1, Z2 and Z3 may each represent CH or N; X is N or CH and Q is O or S; it being understood that if m and n each are 0, then A is CH2; and salts of such compounds.
    本发明涉及式I的抗菌化合物,其中R1是烷基或卤素; U和V各自独立地是CH或N; 是键或不存在; W是CH或N或,当不存在时,W是CH2或NH,但U、V和W不全是N; A是键或 ; R2是H或,如果A是 ,则也可以是OH; m和n各自独立地是0或1; D是 或键; G代表基,该基在间位和/或对位上被一次或两次取代,取代基选择自烷基,(C1-C3)烷基和卤素,或G是G1或G2基团,其中Z1,Z2和Z3可以各自代表CH或N; X是N或CH,Q是O或S; 如果m和n各自为0,则理解A是 ;以及这种化合物的盐。
  • Tricyclic oxazolidinone antibiotic compounds
    申请人:Hubschwerlen Christian
    公开号:US08618092B2
    公开(公告)日:2013-12-31
    The invention relates to antibacterial compounds of formula I wherein is a bond or is absent, V is CH, CR6 or N; R0 is H or, if is a bond, may also be alkoxy; R1 is notably H or halogen; U is CH or N when is a bond, or, if is absent, U is CH2, NH or NR9; R2 is H, alkylcarbonyl or —CH2—R3; R3 is H, alkyl or hydroxyalkyl; R4 is H or, if n is not 0 and R5 is H, may also be OH; R5 is H, alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, carboxy or alkoxycarbonyl; R6 is hydroxyalkyl, carboxy, alkoxycarbonyl or —(CH2)q—NR7R8, q being 1, 2 or 3 and each of R7 and R8 independently being H or alkyl or R7 and R8 forming with the N atom bearing them a ring; R9 is alkyl or hydroxyalkyl; A is —(CH2)p—, —CH2CH2CH(OH)— or —COCH2CH(OH)—; G is substituted phenyl or G1 or G2 wherein Q is O or S and X is CH or N; and Y1, Y2 and Y3 may each be CH or N; and n is 0 when A is —CH2CH2CH(OH)— or —COCH2CH(OH)—, and n is 0, 1 or 2 when A is —(CH2)p—, p being 1, 2, 3 or 4, with the proviso that the sum of n and p is then 2, 3 or 4; and to salts of such compounds.
    本发明涉及公式I的抗菌化合物,其中 为键或不存在,V为CH,CR6或N; R0为H或,如果 为键,则也可以是烷基; R1特别是H或卤素; 当 为键时,U为CH或N,或者如果 不存在,则U为CH2,NH或NR9; R2为H,烷基羰基或— —R3; R3为H,烷基或羟基烷基; R4为H,或者如果n不为0且R5为H,则也可以是OH; R5为H,烷基,羟基烷基,基烷基,烷基烷基,羧基或烷羰基; R6为羟基烷基,羧基,烷羰基或—( )q—NR7R8,其中q为1、2或3,每个R7和R8独立地为H或烷基,或者R7和R8与它们所带的N原子形成环; R9为烷基或羟基烷基; A为—( )p—、— CH(OH)—或—CO CH(OH)—; G为取代基或G1或G2,其中Q为O或S,X为CH或N; Y1、Y2和Y3可以各自为CH或N; 当A为— CH(OH)—或—CO CH(OH)—时,n为0,当A为—( )p—,p为1、2、3或4时,n为0、1或2,但总和n和p为2、3或4;以及这些化合物的盐。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫